Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin G (IgG) is widely used in clinical practice for the prevention and treatment of certain viral infections, particularly in immunocompromised patients. Scientific studies and clinical guidelines support the use of intravenous immunoglobulin (IVIG), which is primarily composed of pooled IgG from healthy donors, for specific viral indications. IgG provides passive immunity by supplying antibodies that can neutralize viruses and support immune defense in individuals unable to mount adequate responses themselves.

IVIG is FDA-approved and supported by strong evidence for post-exposure prophylaxis of certain viral infections, such as measles, hepatitis A, and varicella-zoster in high-risk individuals (e.g., those with immunodeficiencies or newborns). For cytomegalovirus (CMV), IVIG is used as adjunctive therapy in transplant recipients. In addition, IVIG is sometimes used off-label for severe or refractory viral infections in immunocompromised hosts, though the evidence base is less robust in these scenarios.

However, for the general population or for the treatment of common viral infections (e.g., influenza, common cold, COVID-19), there is limited or no scientific evidence supporting routine use of IgG. The efficacy of IVIG depends on the presence of high-titer antiviral antibodies in the product, which can vary. Overall, the use of IgG for viral infections is scientifically validated in targeted, high-risk settings, with a moderate to high level of supporting evidence.

More about Immunoglobulin G
More about Infection (viral)

Other ingredients used for Infection (viral)

Other health conditions supported by Immunoglobulin G

Products containing Immunoglobulin G